Pfizer COVID-19 Vaccine Associated with Dramatic Decline in Antibody Protection Just Weeks After 2nd & 3rd Dose

Danish physicians and scientists affiliated with that Nordic nation's prestigious Statens Serum Institut in Copenhagen and Zealand University Hospital in Naestved report that a study involving 128 patients published in the peer-reviewed JAMA Network Open reveals a troubling vaccine effectiveness finding associated with the Pfizer&rsquo;s COVID-19 mRNA-based vaccine, BNT162b2. The results of this study suggest a dramatic decline in protection, and given mounting Omicron-based surges, more calls for booster doses for vulnerable populations. Investigating the impact of two and three mRNA-based does on 128 people, the Danish physician-investigator-based team found levels of omicron-specific &ldquo;neutralizing&rdquo; antibodies waning in strength after the second and third Pfizer jab. Unfortunately, within weeks the jab antibody levels meant to protect the individual from infection and severe disease wane within weeks and correspond with other studies reported by this media showcasing subpar performance and vaccine durability when compared to applicability to other COVID-19 variants, such as delta.
This study was conducted by the Statens Serum Institut, an institute under the Danish Ministry of Health, and the data derives from ongoing national infectious disease surveillance activity using excess biological material made available under Section 222 of the Danish Health Act.